Related Experiment Video

Updated: Feb 25, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Targeting HER2 in Advanced Breast Cancer

Xiaofu Zhu1, Anil Abraham Joy2

  • 1Division of Medical Oncology, Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta and Cross Cancer Institute, 11560 University Avenue, Edmonton, AB, Canada, T6G 1Z2. Xiaofu.Zhu@albertahealthservices.ca.

Methods in Molecular Biology (Clifton, N.J.)
|August 10, 2017
PubMed

Insights

Targeted anti-HER2 therapies have significantly improved outcomes for patients with HER2-positive breast cancer. This review covers current data from clinical trials and future advances for metastatic disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Human epidermal growth factor receptor 2 (HER2) is an oncogene amplified in ~20% of breast cancers.
  • HER2 amplification is associated with a poorer prognosis without targeted treatment.
  • Targeted anti-HER2 therapies have revolutionized treatment for metastatic HER2-positive breast cancer.

Purpose of the Study:

  • To review data from completed randomized phase III clinical trials on targeted anti-HER2 therapies.
  • To discuss emerging advances addressing unmet needs in metastatic HER2-positive breast cancer.

Main Methods:

  • Systematic review of randomized phase III clinical trials.
  • Analysis of data on efficacy and safety of anti-HER2 agents.
  • Discussion of ongoing and future therapeutic strategies.

Main Results:

  • Targeted anti-HER2 therapies are standard of care for first-line and subsequent treatment settings.
  • These therapies have dramatically improved disease control and survival rates.
  • Evidence from phase III trials supports their efficacy in metastatic HER2-positive breast cancer.

Conclusions:

  • Targeted anti-HER2 therapies represent a major advancement in breast cancer treatment.
  • Continued research is essential to address remaining challenges and improve patient outcomes.
  • Emerging therapies hold promise for further enhancing treatment efficacy.
Keywords:
Breast cancerClinical trialsHER2Therapies

More Related Videos

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

11.5K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K